FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 318:663-670 March 17, 1988 Number 11 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

To improve criteria for entry into future trials of immunosuppression, we enrolled 40 children with recent-onset Type I insulin-dependent diabetes in a pilot trial of cyclosporine. Twenty-seven patients were able to discontinue insulin therapy 48 +/- 5 days after the start of immunosuppression. At four months, their fasting and postprandial blood glucose concentrations averaged 110 and 160 mg per deciliter (6.1 and 8.9 mmol per liter) with a mean hemoglobin A1c level of 6.15 percent. Seventy-five percent of these patients with early remission still did not need insulin at 12 months, and their glycemic control was similar to that at 4 months. The major differences between the 27 patients with remission and the 13 without remission were the duration of symptoms before diagnosis (26.8 vs. 48.0 days, P less than 0.01), the degree of weight loss (3.2 vs. 10 percent of body weight, P less than 0.001), the initial hemoglobin A1c level (10.7 vs. 13.2 percent, P less than 0.001), and the frequency of ketoacidosis (11 vs. 61.5 percent, P less than 0.001). The lesser degree of weight loss was the strongest independent predictor of remission. The response of C-peptide to intravenous glucagon (0.50 vs. 0.17 pmol per milliliter, P less than 0.05) was also an independent predictor. No differences were observed between the two groups of patients in age, sex, HLA phenotype, autoantibodies to insulin or islet-cell antigens, or doses or trough levels of cyclosporine. Only minimal manifestations of toxicity were detected over the period of observation. We conclude that early treatment with cyclosporine in children with recent-onset Type I diabetes can induce remission from insulin dependence, with half the patients not requiring insulin after a full year.

Source Information

Service d'Endocrinologie Pediatrique, Hopital Saint-Vincent de Paul, Paris, France.

This article has been cited by other articles:

• Sherry, N. A., Chen, W., Kushner, J. A., Glandt, M., Tang, Q., Tsai, S., Santamaria, P., Bluestone, J. A., Brillantes, A.-M. B., Herold, K. C. (2007). Exendin-4 Improves Reversal of Diabetes in NOD Mice Treated with Anti-CD3 Monoclonal Antibody by Enhancing Recovery of {beta}-Cells. Endocrinology 148: 5136-5144 [Abstract] [Full Text]  
• Ross, L. F., Philipson, L. H. (2007). Ethics of Hematopoietic Stem Cell Transplantation in Type 1 Diabetes Mellitus. JAMA 298: 285-285 [Full Text]  
• Perone, M. J., Bertera, S., Tawadrous, Z. S., Shufesky, W. J., Piganelli, J. D., Baum, L. G., Trucco, M., Morelli, A. E. (2006). Dendritic Cells Expressing Transgenic Galectin-1 Delay Onset of Autoimmune Diabetes in Mice. J. Immunol. 177: 5278-5289 [Abstract] [Full Text]  
• Seyfert-Margolis, V., Gisler, T. D., Asare, A. L., Wang, R. S., Dosch, H. M., Brooks-Worrell, B., Eisenbarth, G. S., Palmer, J. P., Greenbaum, C. J., Gitelman, S. E., Nepom, G. T., Bluestone, J. A., Herold, K. C. (2006). Analysis of T-Cell Assays to Measure Autoimmune Responses in Subjects With Type 1 Diabetes: Results of a Blinded Controlled Study. Diabetes 55: 2588-2594 [Abstract] [Full Text]  
• Lernmark, A. (2005). Type 1 Diabetes -- Does Suppressing T Cells Increase Insulin?. NEJM 352: 2642-2644 [Full Text]  
• Herold, K. C., Gitelman, S. E., Masharani, U., Hagopian, W., Bisikirska, B., Donaldson, D., Rother, K., Diamond, B., Harlan, D. M., Bluestone, J. A. (2005). A Single Course of Anti-CD3 Monoclonal Antibody hOKT3{gamma}1(Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years after Onset of Type 1 Diabetes. Diabetes 54: 1763-1769 [Abstract] [Full Text]  
• Palmer, J. P., Fleming, G. A., Greenbaum, C. J., Herold, K. C., Jansa, L. D., Kolb, H., Lachin, J. M., Polonsky, K. S., Pozzilli, P., Skyler, J. S., Steffes, M. W. (2004). C-Peptide Is the Appropriate Outcome Measure for Type 1 Diabetes Clinical Trials to Preserve {beta}-Cell Function: Report of an ADA Workshop, 21-22 October 2001. Diabetes 53: 250-264 [Abstract] [Full Text]  
• Christie, M. R., Molvig, J., Hawkes, C. J., Carstensen, B., Mandrup-Poulsen, T., the Canadian-European Randomised Control Trial Gro, (2002). IA-2 Antibody-Negative Status Predicts Remission and Recovery of C-Peptide Levels in Type 1 Diabetic Patients Treated With Cyclosporin. Diabetes Care 25: 1192-1197 [Abstract] [Full Text]  
• Herold, K. C., Hagopian, W., Auger, J. A., Poumian-Ruiz, E., Taylor, L., Donaldson, D., Gitelman, S. E., Harlan, D. M., Xu, D., Zivin, R. A., Bluestone, J. A. (2002). Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus. NEJM 346: 1692-1698 [Abstract] [Full Text]  
• Confavreux, C, Vukusic, S, Grimaud, J, Moreau, T (1999). Clinical progression and decision making process in multiple sclerosis. Mult Scler 5: 212-215  
• Atkinson, M. A., Maclaren, N. K. (1994). The Pathogenesis of Insulin-Dependent Diabetes Mellitus. NEJM 331: 1428-1436 [Full Text]  
• Bohme, J, Schuhbaur, B, Kanagawa, O, Benoist, C, Mathis, D (1990). MHC-linked protection from diabetes dissociated from clonal deletion of T cells. Science 249: 293-295 [Abstract]  
• (1988). CYCLOSPORINE FOR RECENT-ONSET JUVENILE DIABETES. JWatch General 1988: 1-1 [Full Text]